Treg Cell-Based Therapies Pipeline Assessment, 2023 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Key Companies - Sangamo Therapeutics, Gentibio, Abata Therapeutics, Nigh

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Treg Cell-Based Therapies pipeline constitutes key companies continuously working towards developing Treg Cell-Based Therapies treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Treg Cell-Based Therapies Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Treg Cell-Based Therapies Market.

The Treg Cell-Based Therapies Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Treg Cell-Based Therapies Pipeline Report: https://www.delveinsight.com/report-store/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Treg Cell-Based Therapies treatment therapies with a considerable amount of success over the years.
• Treg Cell-Based Therapies companies working in the treatment market are HCW Biologics, Sangamo Therapeutics, Gentibio, Abata Therapeutics, NightHawk Biosciences, Sangamo Therapeutics, Quell Therapeutics Limited, Coya Therapeutics, Orca Bio, and others, are developing therapies for the Treg Cell-Based Therapies treatment
• Emerging Treg Cell-Based Therapies therapies such as - HCW9302, KITE-037, GNTI-122, ABA-101, PTX-35, TX200, QEL-001, Coya 101, Orca-T, and others are expected to have a significant impact on the Treg Cell-Based Therapies market in the coming years.
• In February 2023, Positive data on Orca-T was presented from the single-center Phase 2 and multi-center Phase 1btrials of patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS) and other hematological malignancies. Outcomes with Orca-T appeared to be further enhanced in patients whoreceived a conditioning regimen of busulfan, fludarabine and thiotepa (BFT)
• In April 2022, A strategic partnership between Quell Therapeutics Ltd and CellisticTM was launched in order to jointly develop a Treg cell treatment platform produced from iPSCs. By utilising CellisticTM's expertise in differentiation and scale-up of iPSC processes for allogeneic cell therapy applications, the partnership aims to facilitate the future expansion of Quell's autologous Treg cell therapy pipeline by adding off-the-shelf, allogeneic Treg cell therapy products
• In August 2022, In order to extend its activities in Seattle and supplement its current R&D enterprise in South San Francisco, Sonoma Biotherapeutics, Inc. announced that it has entered into a leasing agreement to create an approximately 83,000 square foot Research and Development (R&D) and Manufacturing Centre.The cutting-edge Centre assisted Sonoma Bio's pipeline of gene-modified Treg treatments for autoimmune and inflammatory illnesses in R&D and mass production
• In August 2022, GentiBio, Inc. announced that it had entered into a collaboration with Bristol Myers Squibb to develop new engineered Treg therapies to re-establish immune tolerance and repair tissue in patients living with inflammatory bowel diseases (IBD). The collaboration brings together GentiBio's proprietary engineered Treg platform for generating scalable, stable, highly-selective, and durable Tregs with Bristol Myers Squibb's leadership in cell therapies and immunology
• In June 2022, Orca Biosystems initiated a randomized Phase III trial for patients with advanced hematologic malignancies undergoing allogeneic hematopoietic cell transplantation with Eether Orca-T, a T-cell-depleted graft with additional infusion of conventional T cells and regulatory T cells, or standard-of-care allogeneic graft
• In December 2022, Orca Bio, presented updated positive clinical data on its lead investigational cell therapy, Orca-T,during an oral presentation at the 64th American Society of Hematology (ASH) Annual Meeting. The data demonstrated a significant improvement in relapse-free survival (RFS) at one year with 87% in 71 patients who received Orca-T and busulfan, fludarabine and thiotepa (BFT) conditioning

Treg Cell-Based Therapies Overview
Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. Early experiences of Treg cell therapy in patients with graft-versus-host disease, type1 diabetes, and organ transplantation have shown that it is feasible, safe, and potentially efficacious in some settings.

Get a Free Sample PDF Report to know more about Treg Cell-Based Therapies Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Treg Cell-Based Therapies Drugs Under Different Phases of Clinical Development Include:
• HCW9302: HCW Biologics
• KITE-037: Sangamo Therapeutics
• GNTI-122: Gentibio
• ABA-101: Abata Therapeutics
• PTX-35: NightHawk Biosciences
• TX200: Sangamo Therapeutics
• QEL-001: Quell Therapeutics Limited
• Coya 101: Coya Therapeutics
• Orca-T: Orca Bio

Treg Cell-Based Therapies Pipeline Therapeutics Assessment
• Treg Cell-Based Therapies Assessment by Product Type
• Treg Cell-Based Therapies By Stage and Product Type
• Treg Cell-Based Therapies Assessment by Route of Administration
• Treg Cell-Based Therapies By Stage and Route of Administration
• Treg Cell-Based Therapies Assessment by Molecule Type
• Treg Cell-Based Therapies by Stage and Molecule Type

DelveInsight's Treg Cell-Based Therapies Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Treg Cell-Based Therapies product details are provided in the report. Download the Treg Cell-Based Therapies pipeline report to learn more about the emerging Treg Cell-Based Therapies therapies at:
https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Treg Cell-Based Therapies Therapeutics Market include:
Key companies developing therapies for Treg Cell-Based Therapies are - Orca Bio, Caladrius Biosciences, Sangamo Therapeutics, Cellenkos, VT BIO, Rapa Therapeutics, Quell Therapeutics, Coya Therapeutics, Sonoma Biotherapeutics, GentiBio, AstraZeneca, TCR² Therapeutics, KSQ Therapeutics, Kyverna Therapeutics, Astellas, Abata Therapeutics, TRACT Therapeutics, Adaptive Biotechnologies, PolTREG, TeraImmune, and others.

Treg Cell-Based Therapies Pipeline Analysis:
The Treg Cell-Based Therapies pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Treg Cell-Based Therapies with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Treg Cell-Based Therapies Treatment.
• Treg Cell-Based Therapies key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Treg Cell-Based Therapies Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Treg Cell-Based Therapies market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Treg Cell-Based Therapies drugs and therapies-
https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Treg Cell-Based Therapies Pipeline Market Drivers
High prevalence of autoimmune and inflammatory diseases, the emergence of new techniques such as next-generation T-cells immunotherapy are some of the important factors that are fueling the Treg Cell-Based Therapies Market.

Treg Cell-Based Therapies Pipeline Market Barriers
However, high cost associated with the Treg Cell-Based Therapies, the complex manufacturing of regulatory T-cell immunotherapies and other factors are creating obstacles in the Treg Cell-Based Therapies Market growth.

Scope of Treg Cell-Based Therapies Pipeline Drug Insight
• Coverage: Global
• Key Treg Cell-Based Therapies Companies: HCW Biologics, Sangamo Therapeutics, Gentibio, Abata Therapeutics, NightHawk Biosciences, Sangamo Therapeutics, Quell Therapeutics Limited, Coya Therapeutics, Orca Bio, and others
• Key Treg Cell-Based Therapies Therapies: HCW9302, KITE-037, GNTI-122, ABA-101, PTX-35, TX200, QEL-001, Coya 101, Orca-T, and others
• Treg Cell-Based Therapies Therapeutic Assessment: Treg Cell-Based Therapies current marketed and Treg Cell-Based Therapies emerging therapies
• Treg Cell-Based Therapies Market Dynamics: Treg Cell-Based Therapies market drivers and Treg Cell-Based Therapies market barriers

Request for Sample PDF Report for Treg Cell-Based Therapies Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/treg-cell-based-therapies-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1 Treg Cell-Based Therapies Report Introduction
2 Treg Cell-Based Therapies Executive Summary
3 Treg Cell-Based Therapies Overview
4 Treg Cell-Based Therapies- Analytical Perspective In-depth Commercial Assessment
5 Treg Cell-Based Therapies Pipeline Therapeutics
6 Treg Cell-Based Therapies Late Stage Products (Phase II/III)
7 Treg Cell-Based Therapies Mid Stage Products (Phase II)
8 Treg Cell-Based Therapies Early Stage Products (Phase I)
9 Treg Cell-Based Therapies Preclinical Stage Products
10 Treg Cell-Based Therapies Therapeutics Assessment
11 Treg Cell-Based Therapies Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Treg Cell-Based Therapies Key Companies
14 Treg Cell-Based Therapies Key Products
15 Treg Cell-Based Therapies Unmet Needs
16 Treg Cell-Based Therapies Market Drivers and Barriers
17 Treg Cell-Based Therapies Future Perspectives and Conclusion
18 Treg Cell-Based Therapies Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:

Treg Cell-Based Therapies Epidemiology
https://www.delveinsight.com/report-store/treg-cell-based-therapies-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Treg Cell-Based Therapies Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:

Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.